Active Ingredient History

  • Now
Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.   Wikipedia

  • SMILES: COC(=O)[C@H](Cc1cccc(c1)C(=N)N)[C@@H](C)NC(=O)c2ccc(cc2)c3cc[n+]([O-])cc3
  • Mol. Mass: 446.51
  • ALogP: 2.42
  • ChEMBL Molecule:
More Chemistry
2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester | 2-(r)-(3-carbamimidoylbenzyl)-3-(r)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester | fxv 673 | otamixaban


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue